Prior studies have identi®ed Fibroblast Growth Factor-8 (Fgf8) as a possible proto-oncogene in mouse mammary tumorigenesis. We now report on the generation of two types of Fgf8 transgenic mice that each utilize the mouse mammary tumor virus (MMTV) promoter. The ®rst transgene (MMTV-Fgf8b) results in the overexpression of the FGF8b isoform exclusively. Male and female MMTV-Fgf8b transgenic mice are viable and fertile. RNA for FGF8b is detected in mammary gland and salivary gland tissues of transgenic mice by Northern blot analysis. Nearly 85% of breeding transgenic female mice developed mammary lobular adenocarcinomas by 12 months of age, while no tumors developed in nontransgenic littermates. Salivary gland tumors occurred in some animals, always in association with mammary tumors. Several MMTV-Fgf8b transgenic mice had lung metastases at necropsy. The second transgene (MMTVFgf8) uses the entire Fgf8 gene and potentially encodes all FGF8 isoforms. Fgf8 is expressed by this transgene in several tissues in addition to those described above, notably the ovaries. The two MMTV-Fgf8 founders developed mammary ductal adenocarcinomas at ®ve and eight months of age, and both displayed ovarian stromal hyperplasia. The founders expressing either transgene did not successfully nurse their pups. These results demonstrate that production of FGF8b, and possibly other FGF8 isoforms, in the mammary and salivary glands contributes to oncogenesis, and that ovarian expression results in stromal hyperplasia.
Introduction
Most carcinogenic processes are multi-step, and understanding the multiple genetic events involved in mammary carcinogenesis may lead to rational interventional strategies (Harris et al., 1992a,b) . As one of these potential steps, alterations and/or over-expression of members of the Fibroblast Growth Factor (FGF) family and their receptors have been described in human breast cancers (Jaakkola et al., 1993; Jacquemier et al., 1994; Penault-Llorca et al., 1995; Payson et al., 1996; Bansal et al., 1997; Yiangou et al., 1997) .
FGFs are secreted peptide growth factors that are thought to have most of their biological eect by binding to membrane receptor tyrosine kinases that transmit intracellular signals that ultimately aect cellular growth and/or dierentiation programs (Basilico and Moscatelli, 1992; Johnson and Williams, 1993; Ornitz et al., 1996) .
As human carcinogenic processes are temporally long and have limited potential for experimental exploitation, animal models of mammary gland carcinogenesis are necessary to rapidly advance our knowledge and our potential for intervention (Harris et al., 1992a,b) . Few mouse models of FGF in mammary gland cancer exist. Insertional activation of Fgf3/int-2 (Dickson et al., 1984) , Fgf4/hst (Peters et al., 1989) , and Fgf8 (MacArthur et al., 1995c; Kapoun and Shackleford, 1997) by mouse mammary tumor virus (MMTV) in murine mammary cancers have been described. Female MMTV-Fgf3 transgenic mice develop mammary gland cancer after several months of epithelial hyperplasia, while male MMTV-Fgf3 mice develop prostatic hypertrophy (Muller et al., 1990; Ornitz et al., 1991) Similarly, MMTV-Fgf7 transgenic mice develop the same phenotype as MMTV-Fgf3 transgenic mice (Kitsberg and Leder, 1996) . Both FGF3 and FGF7 proteins activate the KGF receptor (FGFR2b) (Miki et al., 1991; Mathieu et al., 1995) , so it is not surprising that these FGFs, when overexpressed in the mammary gland as transgenes, result in similar mammary cancer phenotypes. Cooperativity of FGFs with Wnt genes in mammary gland cancer development has been demonstrated by two approaches: (1) more rapid tumorigenesis by insertional activation following MMTV infection of transgenic mice (Shackleford et al., 1993; Lee et al., 1995; MacArthur et al., 1995c; Kapoun and Shackleford, 1997) ; and (2) more rapid tumorigenesis in bitransgenic Fgf3/Wnt1 mice compared to the single transgenic mice (Kwan et al., 1992) .
Fgf8 was originally identi®ed as a gene encoding an androgen inducible growth factor (Tanaka et al., 1992) . We identi®ed Fgf8 as a gene that is frequently activated by MMTV insertion in MMTV-Wnt1 transgenic mice (MacArthur et al., 1995c; Kapoun and Shackleford, 1997) . Fgf8 encodes multiple protein isoforms by alternative splicing at the 5' end of the gene (Crossley and Martin, 1995; MacArthur et al., 1995c) , and these protein isoforms activate FGFR2c, FGFR3c, and FGFR4 (MacArthur et al., 1995b; Blunt et al., 1997) . Normal functions of Fgf8 are thought to include paracrine signaling during gastrulation, limb and central nervous system development (Crossley and Martin, 1995; Crossley et al., 1996a,b; Meyers et al., 1998) . FGF8b protein can transform NIH3T3 cells, demonstrating an oncogenic potential for at least one of the FGF8 isoforms (Kouhara et al., 1994; MacArthur et al., 1995a) . FGF8 expression has been described in human breast cancer samples (Tanaka et al., 1995; Payson et al., 1996) . Here, we demonstrate that overexpression of FGF8b, and possibly other isoforms, in the mammary gland results in mammary tumorigenesis, con®rming that overexpression of one or more isoforms of Fgf8 is oncogenic for the mammary gland.
Results

Generation of MMTV-Fgf8 transgenic mice
To determine the mammary oncogenicity of Fgf8, we produced two transgenes under the control of the MMTV LTR (Figure 1 ). The MMTV-Fgf8b transgene contains the Fgf8b cDNA and encodes only the FGF8b protein isoform (Figure 1a ). The MMTVFgf8 transgene (Figure 1c ) was cloned from genomic DNA from a previously described mammary tumor possessing a MMTV insertion into the Fgf8 gene (tumor 86, (MacArthur et al., 1995c) ). PCR analysis of tail DNA from potential MMTV-Fgf8b founder transgenic animals revealed three founder animals that possessed the 179 bp ampli®ed fragment ( Figure  1b) . The lower molecular weight fragment in Figure 1b likely represents a`primer-dimer' artifact, since it is observed when the primers are added and independent of whether template DNA is present (data not shown). Mouse #4 was a male that never transmitted the transgene to any of his 70 ospring (data not shown). Mouse #14 was a female that transmitted the transgene to her ospring, but none of the ospring expressed the transgene (data not shown). Mouse #16 (8b-16) was a female whose ®rst two litters died within 48 h of birth; all ospring appeared normal at birth. Subsequent litters were rescued with foster mothers, and the transgene was found to be transmitted and expressed. Although the ospring from 8b-16 required rescue by foster mothers, subsequent generations of this transgenic line did not require foster mother rescue. Southern blot analysis of potential founders of the MMTV-Fgf8 transgene revealed two female founders (Mouse #3 and #17, Figure 1d ). Both MMTV-Fgf8 transgenic animals produced pups that died within 48 h of birth, possibly due to an inability to deliver milk.
Expression of MMTV-Fgf8 transgenes
Northern blot analysis of tissue RNAs from the 8b-16 transgenic line demonstrated strong expression of the transgene in normal parous mammary tissue and in mammary tumors with weaker expression in salivary glands (Figure 2a) .
The MMTV-Fgf8 transgenic founder #17 expressed the transgene in a somewhat dierent pattern, with highest levels of Fgf8 RNA in mammary tumor, parous mammary glands, lung and ovary, and lower level in kidneys, salivary gland and spleen (Figure 2b ). The MMTV-Fgf8 transgenic founder #3 also expressed high levels of Fgf8 RNA in mammary tumor and parous mammary glands (Figure 2b) . A direct comparison showed that the extent of expression of the MMTVFgf8 transgene was very similar to that of the MMTVFgf8b transgene in mammary glands and mammary tumors (Figure 2b ).
To further identify the cells responsible for transgene expression, we employed in situ hybridization of frozen tissue sections, using an anti-sense Fgf8b riboprobe (Heikinheimo et al., 1994) . We observed weak expression of the MMTV-Fgf8b transgene in the ductal epithelium of the mammary gland ( Figure (Figure 2 ) and localize its expression to the epithelial component of the hyperplastic and malignant mammary glands, as in MMTV-Fgf3 and MMTV-Fgf7 transgenic mice (Muller et al., 1990; Ornitz et al., 1991; Kitsberg and Leder, 1996) .
Tumor incidence in MMTV-Fgf8 transgenic mice.
Forty-two transgenic females, 20 transgenic males, and 20 non-transgenic littermates (10 males and 10 females) from the MMTV-Fgf8b transgenic line 8b-16 were followed for the development of tumors (Figure 4) . The transgenic females were separated into two groups: one group remained virgins (23 mice), and the other group was allowed to breed (19 mice). None of the 20 nontransgenic control littermates developed any type of tumor in the one year they were followed (Figure 4 ). Breeding transgenic females developed mammary gland tumors with a several month latency (Figure 4) . The majority of tumors in this breeding cohort developed after six months of age and after multiple pregnancies (average number of pregnancies was six). Four virgin transgenic females developed fairly rapid tumors (all less than 4 months of age), but the remainder of the virgin transgenic mice did not develop tumors after one year (Figure 4) . One transgenic male developed a mammary gland tumor (Figure 4 ). Salivary gland tumors were seen in three mice, all of which had 
Histopathology of MMTV-Fgf8 transgenic mice
Histopathological analysis of tissues from MMTVFgf8b transgenic mice (line 8b-16) demonstrated ductal hyperplasia in the breeding females (Figure 5a ), which preceded tumor development. The mammary tumors in this MMTV-Fgf8b transgenic line were lobular carcinomas in all cases (including the transgenic male) (Figure 5b ,c, and data not shown). In eight of 20 of these MMTV-Fgf8b transgenic mice with mammary tumors, pleural-based metastases in the lungs were observed both grossly (data not shown) and microscopically (Figure 5d ). Three animals with mammary tumors also had coincidental salivary gland tumors. These salivary gland tumors were adenocarcinomas that were well-circumscribed in all cases ( Figure  5e ). Non-transgenic littermates (10 male, 10 female) are indicated by (6), and transgenic males are indicated by (*). The total number of animals followed in each group are indicate in parentheses. The animals were followed for a maximum of 12 months In the MMTV-Fgf8 founder animals, ductal hyperplasia ( Figure 6a ) was seen in most nontumorous mammary glands, and an adenoma ( Figure  6b ) was present in one of the mammary glands of these animals at the time of the development of in®ltrating ductal adenocarcinomas (Figure 6c ). Metastases were not observed in these two animals. Interestingly, these two animals were observed to have ovarian enlargement at necropsy, and histological examination of ovarian sections revealed stromal hyperplasia (Figure  6d ), presumably as a direct result of transgene expression in this tissue (Figure 2b) .
Discussion
Prior studies suggested that activation and inappropriate expression of Fgf8 by MMTV insertion might be involved in mammary gland cancer development in mice (MacArthur et al., 1995c; Kapoun and Shackleford, 1997). FGF8 expression has been observed in human breast cancer cell lines (Payson et al., 1996; Wu et al., 1997) , and the FGF8b protein isoform has been shown to transform NIH3T3 cells (Kouhara et al., 1994; MacArthur et al., 1995a) . We now demonstrate that overexpression of the FGF8b isoform in the mammary and salivary glands (Figures 2 and 3) , under the control of the MMTV LTR, results in the development of carcinomas of both tissues ( Figure 5 ). Similarly, a transgene capable of overexpressing all of the FGF8 protein isoforms in several tissues results in the development of carcinomas of the mammary gland and ovarian stromal hyperplasia ( Figure 6 ). Mammary ductal hyperplasia was seen in both transgenic lines, preceding the development of mammary adenocarcinomas in these transgenic lines (Figures 5 and 6 ). Although only one line of MMTV-Fgf8b transgenic mice was obtained, the expression patterns of the transgene, the corresponding phenotypes in the expressing tissues, and the similarity to the MMTVFgf8 transgenic mice all strongly suggest that the observed phenotypes are due to the MMTV-Fgf8b transgene and not to insertion site eects.
In both MMTV-Fgf8 transgenic lines, the development of most of the mammary adenocarcinomas was prolonged (Figure 4 ) and preceded by mammary ductal hyperplasia in the female mice (Figures 5 and 6 ). Only one tumor was seen in a male animal, and only four tumors in virgin females (Figure 4) . The increased incidence of tumors in breeding females is likely due to higher expression of the transgene in the mammary glands with hormonal eects on the MMTV LTR (Haraguchi et al., 1992; Le Ricousse et al., 1996; Haraguchi et al., 1997) , together with the cell proliferation induced by cycles of pregnancy. The prolonged tumor latency indicates that additional genetic events are necessary for tumor development. Activated Wnt genes are likely candidates for one of these events in these tumors, given the strong oncogenic cooperation between FGFs and Wnts (Kwan et al., 1992; Shackleford et al., 1993; Lee et al., 1995; Kapoun and Shackleford, 1997) .
Although mammary adenocarcinomas developed in both MMTV-Fgf8 transgenic lines, the histology was dierent in the two transgenic lines. MMTV-Fgf8b mice developed lobular adenocarcinomas ( Figure 5 ) and MMTV-Fgf8 mice developed ductal carcinomas ( Figure 6 ). Possible explanations for this dierence in mammary gland cancer histology between these two Fgf8 transgenes include: (1) dierent levels of transgene expression; (2) dierent spatial or temporal expression of the transgenes in the mammary gland; and (3) eects of heterodimerization of FGF8 isoforms. Dierent quantitative levels of expression are possible, due to dierences in transgene copy number, or insertion site. However, we did not detect signi®cant dierences in expression of the transgenes, as detected by Northern blot (Figure 2b) . Dierent spatial or temporal expression patterns in the mammary gland of the two transgenes might be due to dierences in the transgene insertion sites, or perhaps more likely to enhancers present in the MMTV-Fgf8 transgene that are not present in the MMTV-Fgf8b transgene. We have previously demonstrated that the dierent FGF8 isoforms interact with the dierent FGFRs in a redundant fashion, with FGF8b activating FGFR2c, FGFR3c, and FGFR4 (MacArthur et al., 1995b; Blunt et al., 1997) . Our work did not address the possibility that dierent FGF8 isoforms might heterodimerize and interact in a quantitatively or qualitatively dierent fashion with the known FGFRs (McKeehan and Kan, 1994) . Thus it is possible that quantitatively or qualitatively dierent interactions due to potential heterodimerization of FGF8 isoforms present in the MMTV-Fgf8 transgenic mammary gland might be responsible for the ductal tumor histology observed in this line.
Another intriguing dierence between the two transgenic lines produced here is the ovarian stromal hyperplasia of the MMTV-Fgf8 transgenic mice (Figure 6 ). This phenotype is rare, if not unique, among mice generated using MMTV LTR-driven transgenes. Since both MMTV-Fgf8 transgenic founders of this transgene displayed the ovarian hyperplasia, it seems probable that the transgene, which consists of the entire Fgf8 gene and at least 6 kb of downstream (1006) genomic sequences, contains enhancers that promote expression in ovarian tissue. Indeed, the ovary is one of the few sites of normal Fgf8 expression in the adult mouse, suggesting that the Fgf8 gene contains such ovary-speci®c enhancers (MacArthur et al., 1995c) .
FGF8b is known to be produced by epithelial cells, and to activate in a paracrine manner FGFR2c, FGFR3c, and FGFR4, which are primarily located in mesenchymal locations (MacArthur et al., 1995b; Ornitz et al., 1996; Blunt et al., 1997) . We demonstrate expression of the MMTV-Fgf8b transgene in the epithelial compartment of the mammary tumors (Figure 3) . Given the observed FGF8b interactions with FGFRs, we would not expect FGF8b to act in an autocrine manner to stimulate mammary epithelial growth and tumorigenesis directly. FGF7 is known to be produced by mesenchymal cells and to interact with epithelially localized FGFR2b, in a paracrine fashion (Rubin et al., 1995; Ornitz et al., 1996) . FGF7 is a physiological stimulus for mammary epithelial growth (Coleman-Krnacik and Rosen, 1994; Imagawa et al., 1994; Ulich et al., 1994) . Furthermore, MMTV-Fgf7 transgenic mice develop mammary adenocarcinomas with lung metastases (Kitsberg and Leder, 1996) , similar to our MMTV-Fgf8b transgenic mice. On the basis of these ®ndings, we speculate that overexpression of FGF8b in the epithelial compartment results in the upregulation of FGF7, or another epithelial growth factor(s), in the mesenchymal compartment of the mammary gland, which then provides the stimulus for mammary epithelial growth, and ultimately ductal hyperplasia and adenocarcinomas. This coupled paracrine stimulation occurs in vertebrate limb development, where FGF10 (an FGF closely related to FGF7) in the limb mesenchyme induces expression of FGF8 in the apical ectodermal ridge, and FGF8 expression in the apical ectodermal ridge maintains FGF10 expression in the mesenchyme (Ohuchi et al., 1997) .
The MMTV-Fgf8b transgenic line displayed a metastatic phenotype, similar to MMTV-Fgf7 transgenic mice (Kitsberg and Leder, 1996) , with several of our animals becoming ill-appearing during the development of the tumors. This is an uncommon phenotype for mouse models of mammary gland cancer. The similarities in the MMTV-Fgf7 and MMTV-Fgf8b transgenic mouse phenotypes, and the possible cross-paracrine interactions between FGF7 and FGF8b make it dicult to sort out which FGF, if either, might be primarily responsible for the metastatic phenotype. Future work looking at the expression dierences in hyperplastic mammary glands, primary tumors, and metastatic lesions from these mice might elucidate unique metastatic genes.
Materials and methods
Preparation of MMTV-Fgf8 transgenes
The MMTV-Fgf8b transgene was prepared by inserting the murine Fgf8b cDNA (MacArthur et al., 1995c) into the EcoRI site of pMMTV-TGFa (Matsui et al., 1990) , thereby replacing TGFa with FGF8b. The pMMTV-Fgf8b plasmid was digested with A¯III (New England Biolabs) and XhoI (Promega), and the 3.4 kb MMTV-Fgf8b transgene ( Figure   1a ) was puri®ed by low melting agarose gel electrophoresis (Life Sciences Tech.), followed by treatment with bAgarase (New England Biolabs), and ethanol precipitation.
The MMTV-Fgf8 transgene was obtained by cloning the 15.5 kb BamHI fragment, containing the env gene 3' of the BamHI site in MMTV, the 3' LTR, and 12 kb of genomic sequence containing Fgf8, from mammary tumor 86 DNA (Figure 1c ) (MacArthur et al., 1995c) . This cloning was accomplished by digesting tumor 86 DNA with BamHI, size selecting the DNA on a low-melting agarose gel and purifying the DNA with b-Agarase. The BamHI-digested DNA was ligated into l-Dash II (Stratagene), packaged into phage, and the resulting phage library screened for the correct insert with the genomic fragment, XE 2.0 ( Figure  1c) , and with a MMTV-env fragment, EB 0.9 (data not shown). The 15.5 kb MMTV-Fgf8 insert from the correct phage was isolated by digestion with BamHI, size selection in a 0.5% agarose gel, and puri®ed using beads from the Lambda Quick Kit (BIO 101, Inc.) and ethanol precipitation.
Generation of MMTV-FGF8 transgenic mice
Pronuclear injection of the MMTV-Fgf8b transgene into C57BL/66SJL F1 hybrid embryos, followed by insertion of the embryos into pseudo-pregnant females, was performed at the NICHD Transgenic Development Facility at the University of Alabama, Birmingham, USA. Potential founder animals were analysed by PCR of tail DNA (1 mg), using a forward primer in the rabbit bglobin intron 2 (5'-GGCAACGTGCTGGTTATTGTG-3') and a reverse primer in the FGF8b cDNA (5'-TCTGCTCCCTCACATGCTGTG-3'). PCR conditions were as follows: 958C for 3 min, then 35 cycles of 948C for 30 s, 578C for 30 s, and 728C for 30 s. Three of 18 potential founders were positive for the 179 bp ampli®ed fragment, signifying possession of the MMTV-Fgf8b transgene (Figure 1b) . The founder mice were bred to FVB mice, and ospring were analysed by the PCR methods above.
MMTV-Fgf8 transgenic mice were prepared by pronuclear injection of the transgene into C57BL/66SJL F1 hybrid fertilized eggs, followed by placement of the embryos into pseudo-pregnant females at the Norris Cancer Center Transgenic Mouse Core Facility of the University of Southern California. Potential founder animals were screened by Southern blot analysis using Bgl II digestion of the DNA and the XE 2.0 probe. Southern blotting was performed as described (MacArthur et al., 1995c) on 10 mg of tail DNA. The normal Fgf8 genomic fragment is 22 kb in size with BglII digestion and XE 2.0 as the probe; the MMTV-Fgf8 transgene fragment is 6 kb in size (Figures 1c  and 1d ).
Analysis of transgene expression
Total RNA was prepared from tissues from transgenic mice by the guanidium isothiocyanate/acid phenol method (Chomczynski and Sacchi, 1987) . RNAs (10 ± 20 mg) were denatured in formaldehyde/HEPES-Acetate-EDTA with 50% formamide, and electrophoresed in 1% agarose/ formaldehyde/HEPES-Acetate-EDTA gels as described (MacArthur et al., 1995c) . Capillary blotting, UV-crosslinking, hybridization to random primed labeled DNA probes, washing and exposure to x-ray ®lm was as described (MacArthur et al., 1995c) .
Histological sections of MMTV-Fgf8b transgenic animals were prepared from tissues either ®xed in 4% paraformaldehyde, or snap frozen in liquid nitrogen. Following ®xation or freezing, the sections were cut by the Washington University Department of Molecular Biology and Pharmacology Histology Core Facility. Fixed sections were stained with hematoxylin and eosin, and photographed with an Olympus BX60 microscope and a Olympus PM-30 automatic photomicrographic system. Frozen sections were subjected to in situ hybridization with 1610 6 counts/min. of 33 P-labeled antisense or sense riboprobes to the FGF8b cDNA, as described (Wilkinson, 1992) . Bright-®eld and dark-®eld photomicroscopy was performed with an Olympus BX60 microscope and a Olympus PM-30 automatic photomicrographic system.
MMTV-Fgf8 transgenic tissues were prepared for histology by ®xing in 10% formalin. Paran-embedded sections were cut, stained in hematoxylin and eosin, and photographed by the Children's Hospital Los Angeles Pathology Core Facility.
